论文部分内容阅读
目的分析乳腺浸润性导管癌组织中免疫分子B7-H3的表达及其与患者的临床病例参数及肿瘤间质中CD3+、CD4+T淋巴细胞浸润程度的相关性。方法收集2009年1月至2009年12月在苏州市立医院北区行手术切除术的乳腺浸润性导管癌患者组织标本88例,免疫组织化学的方法检测乳腺浸润性导管癌组织中免疫分子B7-H3及CD3、CD8指标的表达。结果乳腺浸润性导管癌组织中有66例免疫分子B7-H3高表达,该分子的表达与患者的年龄、性别、淋巴结的转移情况、肿瘤的大小、肿瘤分期无相关性(P>0.05),但与患者HER2基因表达相关(P<0.05)。且该分子在乳癌中的表达水平与浸润的T淋巴细胞呈正相关。结论免疫分子B7-H3的表达在乳腺浸润性导管癌组织的诊断和预后判断中具有潜在的临床应用价值。
Objective To analyze the expression of B7-H3 in breast invasive ductal carcinoma and its relationship with the clinical parameters and the infiltration of CD3 + and CD4 + T lymphocytes in tumor interstitium. Methods Totally 88 patients with invasive ductal carcinoma of the breast underwent surgical resection in the northern district of Suzhou Municipal Hospital from January 2009 to December 2009 were collected. Tissue samples of breast invasive ductal carcinoma were collected. Immunohistochemistry was used to detect the expression of B7- H3 and CD3, CD8 indicators of expression. Results The expression of B7-H3 in breast invasive ductal carcinomas was high, and the expression of B7-H3 was not correlated with the age, sex, lymph node metastasis, tumor size and tumor stage (P> 0.05) But correlated with HER2 gene expression (P <0.05). The expression level of this molecule in breast cancer was positively correlated with infiltrating T lymphocytes. Conclusion The expression of immune molecule B7-H3 has potential clinical value in the diagnosis and prognosis of breast invasive ductal carcinoma.